MC38-Pd-l1 Knockout Tumor Cell Line

Knockout Immune Checkpoint Cell Lines

Design of the MC38-Pd‑l1 Knockout

The MC38 cell line was derived from C57BL/6 murine colon adenocarcinoma cells. We generated a MC38-Pd-l1 clonal cell line invalidated for murine Pd-l1 (Cd274).

Applications in immuno-oncology

The MC38-Pd-l1 Knockout clones can be used for target validation and mechanistic studies.

Humanized MC38-hPD-L1 cell line:
Use our humanized MC38-hPD-L1 cell line for in vivo tumor growth assays in syngeneic models.


Request a quote here to get pricing, offers and MC38-Pd-l1 Knockout model information by phone or email.


MC38-Pd-l1 Knockout features

  • Invalidated for murine Pd-l1
  • Impaired in vivo tumor growth upon subcutaneous injection in fully immunocompetent mice

MC38-Pd-l1 Knockout validation*

MC38-Pd-l1 KO ICP model validation 1

Invalidation of murine Pd-l1 in MC38-Pd-l1 Knockout cells

Expression analysis by FACS. Pd-l1 expression in MC38‑mPd‑l1 Knockout (KO) clone and wild-type control clone.

MC38-Pd-l1 KO ICP model validation 2

Loss of murine Pd-l1 impairs tumor growth in vivo

Wild-type C57BL/6 mice were injected (s.c.) with 1x105 A) MC38 or B) MC38-Pd-l1 Knockout (KO) cells. Tumor growth was measured every 2 to 3 days. Tumor size (mm3)=(width2 x length)/2. 10 mice were injected per group, with 8 mice developing tumors for MC38 injected groups, and 2 mice for the MC38-Pd-l1 Knockout injected group.

* For more validation data please contact us.


Geoffrey Parriott, Kelsey Deal, Shane Crean, Elle Richardson, Emily Nylen, Amorette Barber.
T-cells Expressing a chimeric-PD1-Dap10-CD3zeta Receptor Reduce Tumour Burden in Multiple Murine Syngeneic Models of Solid Cancer.
Immunology. 2020 Mar 7.

Ready to be shipped to your lab

  • Biosafety level BSL1, according to Kerafast guidelines (parental cell line provider)
  • Studies can be carried out at your site or at your favorite CRO
  • Models provided with FTO on patent-protected technologies used for model generation

Are you looking for another target?
Please contact us.